| 新型冠状病毒感染的肺炎发病机制和治疗策略:肺癌免疫检查点抑制剂相关不良事件的启发 |
| |
| 引用本文： | 刘宝东. 新型冠状病毒感染的肺炎发病机制和治疗策略:肺癌免疫检查点抑制剂相关不良事件的启发[J]. 中国胸心血管外科临床杂志, 2020, 0(5): 597-599 |
| |
| 作者姓名： | 刘宝东 |
| |
| 作者单位： | 首都医科大学宣武医院胸外科 |
| |
| 摘 要： | 2019年12月以来,中国武汉陆续发现了多例新型冠状病毒感染的肺炎患者,其影像学表现与肺癌免疫检查点抑制剂(immune checkpoint inhibitors,ICI)相关肺炎相似,因此推测它们可能有相似的发病机制和治疗策略。在此予以综述,供抗疫前线专家组参考,以利于降低病死率。
|
| 关 键 词： | 新型冠状病毒感染的肺炎 肺癌 免疫检查点抑制剂 免疫相关不良事件 |
Pathogenesis and treatment strategies of novel coronavirus pneumonia:Reflections on immune checkpoint inhibitor-related adverse events in lung cancer |
| |
| LIU Baodong. Pathogenesis and treatment strategies of novel coronavirus pneumonia:Reflections on immune checkpoint inhibitor-related adverse events in lung cancer[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 0(5): 597-599 |
| |
| Authors: | LIU Baodong |
| |
| Affiliation: | (Department of Thoracic Surgery,Xuanwu Hospital,Capital Medical University,Beijing,100053,P.R.China) |
| |
| Abstract: | In December 2019,an outbreak of pneumonia associated with the coronavirus disease 2019(COVID-19)occurred in Wuhan,China.The lung imaging finding is like that of the lung cancer immune checkpoint inhibitors(ICI)associated pneumonia.Therefore,we speculated that they may have similar pathogenesis and treatment strategies,which is reviewed in this article in order to provide some reference to timely and effectively reduce the fatality rate of COVID-19. |
| |
| Keywords: | Coronavirus disease 2019(COVID-19) lung cancer immune checkpoint inhibitors immune-related adverse events |
| 本文献已被 维普 等数据库收录！ |
